nach oben

PharmacoEconomics

Erschienen in:

01.04.2002 | Original Research Article

Cost Effectiveness of Esomeprazole Compared with Omeprazole in the Acute Treatment of Patients with Reflux Oesophagitis in the UK

verfasst von: Peter Wahlqvist, Ola Junghard, Andy Higgins, Jonathan Green

Erschienen in: PharmacoEconomics | Ausgabe 4/2002

Einloggen, um Zugang zu erhalten

Abstract

Background: Clinical studies have demonstrated that esomeprazole is superior to omeprazole for the acute treatment of reflux oesophagitis.

Objective: To compare the cost effectiveness of esomeprazole 40mg once daily with omeprazole 20mg once daily in patients with reflux oesophagitis.

Methods: Pooled data were used from three 8-week clinical trials comparing the efficacy and safety of esomeprazole 40mg once daily and omeprazole 20mg once daily for the acute treatment of reflux oesophagitis. A simple decision analysis model, using UK direct medical costs, compared the cost effectiveness of the two treatments. Healing probabilities derived from the clinical studies using the Life Table method were used to estimate the effectiveness and cost of treating 100 patients with reflux oesophagitis. Patient management assumptions were based on a clinical management survey involving 25 UK physicians.

Perspective: UK National Health Service.

Results: After 4 weeks’ therapy, the Life Table estimated the oesophageal healing rate to be 77.7% in esomeprazole 40mg once-daily recipients (n = 2446), compared with 67.6% in omeprazole 20mg once-daily recipients (n = 2431; p < 0.001). The corresponding values after 8 weeks’ treatment were 93.4% and 86.2%, respectively (p < 0.001). The model predicted that when considering healing probabilities over 8 weeks, esomeprazole 40mg once daily produced total direct cost savings of £1290 (14%) when compared with omeprazole 20mg once daily. When considering the cost of treating patients who had failed treatment (defined as patient not healed as assessed by endoscopy) after 8 weeks, the cost advantage for esomeprazole was even greater.

Conclusion: Esomeprazole 40mg once daily is cost effective compared with omeprazole 20mg once daily in the acute treatment of patients with reflux oesophagitis; esomeprazole provides greater effectiveness at a lower cost.

National Institute for Clinical Excellence 2000. Guidance on the use of Proton Pump Inhibitors (PPIs) in the treatment of dyspepsia [online]. Available from URL: http://www.nice.org.uk [Accessed 2002, Mar 20]

Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 24–9PubMedCrossRef

Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1995; 30 Suppl. 211: 35–8CrossRef

Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997; 11: 755–63PubMedCrossRef

Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965–73PubMedCrossRef

Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119–24PubMedCrossRef

Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172–80PubMedCrossRef

Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux oesophagitis. Am J Gastroenterol 1996; 91: 1749–57PubMed

Corinaldesi R, Valentini M, Belaïche J, et al. Pantoprazole and omeprazole in the treatment of reflux esophagitis: a European multicentre study. Aliment Pharmacol Ther 1995; 9: 667–71PubMedCrossRef

10.

Hallerbäck B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994; 107: 1305–11PubMed

11.

Hatlebakk JC, Berstad A. Lansoprazole 15 and 30mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11 (2): 365–72CrossRef

12.

Mössner J, Holscher AH, Herz R, et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321–6PubMedCrossRef

13.

Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30mg versus omeprazole 40mg in the treatment of reflux oesophagitis grade II, III and IVA (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 1996; 8: 1101–6PubMedCrossRef

14.

Goeree R, O’Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999; 16: 679–97PubMedCrossRef

15.

Dent J, Jones R, Kahrilas P, et al. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001; 322: 344–7PubMedCrossRef

16.

Dent J, Brun J, Fendrick AM, on behalf of the General Workshop Group, et al. An evidence-based appraisal of reflux disease management: The General Workshop Report. Gut 1999; 44 Suppl. 2: S1–16CrossRef

17.

Röhss K, Wilder-Smith CH, Claar-Nilsson C, et al. Esomeprazole 40 mg provides more effective acid control that standard doses of all other proton pump inhibitors [abstract]. Gastroenterology 2001; 120: A419

18.

Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial. Aliment Pharmacol Ther 2000; 14 (10): 1249-58PubMedCrossRef

19.

Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65PubMedCrossRef

20.

Läkemedelsmonografier -Nexium (esomeprazol). Information från Läkemedelsverket 2000; 11 (5): 73–6.

21.

Wesley D. Life Table analysis. J InsurMed 1998; 30 (4): 247–54

22.

Netten A, Dennett J. Unit costs of health and social care 1998. Canterbury: Personal Social Services Research Unit, University of Kent, 1999

23.

Cambridge Health Database 1998. Cambridge Pharma Consultancy.

24.

MIMS (Monthly Index of Medical Specialities). London: Haymarket Medical Ltd., 2000 Oct

25.

Wahlqvist P, Higgins A, Green J. Management of GORD in the UK: results of a survey. Eur J Intern Med 2001; 12: A273–4

26.

Bate CM. Cost effectiveness of omeprazole in the treatment of reflux oesophagitis. Br J Med Econ 1991; 1: 53–61

27.

Bate CM, Richardson PDI. A one year model for the cost effectiveness of treating reflux esophagitis. Br J Med Econ 1992; 2: 5–11

28.

Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs Survey. J Clin Outcomes Management 2000; 7: 29–34

29.

Revicki DA, Wood M, Maton PN, et al. The impact of gastrooesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252–8PubMedCrossRef

30.

Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastrooesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995; 41: 126–36PubMed

31.

Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine: results from a multi-center clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 19–27PubMed

32.

Henke CJ, Levin TR, Henning JM, et al. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organisation. Am J Gastroenterol 2000; 95: 788–92PubMedCrossRef

33.

Wahlqvist P, Carlsson J, Stålhammar N-O, et al. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD): results from a cross-sectional study. Value Health 2002; 5: 106–13PubMedCrossRef

Titel: Cost Effectiveness of Esomeprazole Compared with Omeprazole in the Acute Treatment of Patients with Reflux Oesophagitis in the UK
verfasst von: Peter Wahlqvist
Ola Junghard
Andy Higgins
Jonathan Green
Publikationsdatum: 01.04.2002
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 4/2002
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200220040-00006

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2002

Enoxaparin

Cost Effectiveness of Proton Pump Inhibitors in Gastro-Oesophageal Reflux Disease Without Oesophagitis

Putting Your Money Where Your Mouth Is

A Monte Carlo Simulation for Modelling Outcomes of AIDS Treatment Regimens

Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma